197 related articles for article (PubMed ID: 7860456)
1. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
Hunt RD; Arnsten AF; Asbell MD
J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456
[TBL] [Abstract][Full Text] [Related]
2. An open trial of buspirone in the treatment of attention-deficit disorder.
Niederhofer H
Hum Psychopharmacol; 2003 Aug; 18(6):489-92. PubMed ID: 12923830
[TBL] [Abstract][Full Text] [Related]
3. Tianeptine as a slightly effective therapeutic option for attention-deficit hyperactivity disorder.
Niederhofer H
Neuropsychobiology; 2004; 49(3):130-3. PubMed ID: 15034228
[TBL] [Abstract][Full Text] [Related]
4. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
Chappell PB; Riddle MA; Scahill L; Lynch KA; Schultz R; Arnsten A; Leckman JF; Cohen DJ
J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1140-6. PubMed ID: 7559307
[TBL] [Abstract][Full Text] [Related]
5. Ginkgo biloba treating patients with attention-deficit disorder.
Niederhofer H
Phytother Res; 2010 Jan; 24(1):26-7. PubMed ID: 19441138
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
7. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
[TBL] [Abstract][Full Text] [Related]
8. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
Boon-yasidhi V; Kim YS; Scahill L
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
[TBL] [Abstract][Full Text] [Related]
9. Guanfacine in children with autism and/or intellectual disabilities.
Handen BL; Sahl R; Hardan AY
J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
[TBL] [Abstract][Full Text] [Related]
10. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
[TBL] [Abstract][Full Text] [Related]
12. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder.
Bilici M; Yildirim F; Kandil S; Bekaroğlu M; Yildirmiş S; Değer O; Ulgen M; Yildiran A; Aksu H
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):181-90. PubMed ID: 14687872
[TBL] [Abstract][Full Text] [Related]
15. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Boellner SW; Earl CQ; Arora S
Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
[TBL] [Abstract][Full Text] [Related]
16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
17. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
Akhondzadeh S; Tavakolian R; Davari-Ashtiani R; Arabgol F; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
